Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACACIA RESEARCH CORPACTG · Entity 5559 | Director | January 02, 2018 | January 04, 2018 |
| Veritone, Inc.VERI · Entity 6925 | Director | June 29, 2018 | July 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACACIA RESEARCH CORP
Report date January 02, 2018 · Filed January 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2025-01-02 | Direct | 100,000 |
Reported balance
After 2018-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-02 · Grant · Acquired 100,000 · Balance 100,000 F1: The option shares are execisable in six equal installments over a three-year term beginning from January 2, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares are execisable in six equal installments over a three-year term beginning from January 2, 2018.
Veritone, Inc.
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,959 |
Reported balance
After 2018-06-29 transaction · row 1
1 source rowRow 1 · 2018-06-29 · Grant · Acquired 4,459 · Balance 23,959 F1: Consists of restricted stock units representing the right to receive upon vesting a total of 4,459 shares of the issuer's common stock. All such restricted stock units will vest on the earlier of (i) June 29, 2019, and (ii) the day immediately preceding the date of the issuer's 2019 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units representing the right to receive upon vesting a total of 4,459 shares of the issuer's common stock. All such restricted stock units will vest on the earlier of (i) June 29, 2019, and (ii) the day immediately preceding the date of the issuer's 2019 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2018 Filed Jul 3, 2018 16:59 UTC | Veritone, Inc. VERI · Entity 6925 | GrantCommon Stock | 4,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-18-001019 · primary_01.xml · nonDerivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,959 F1 · shares: Consists of restricted stock units representing the right to receive upon vesting a total of 4,459 shares of the issuer's common stock. All such restricted stock units will vest on the earlier of (i) June 29, 2019, and (ii) the day immediately preceding the date of the issuer's 2019 annual meeting of stockholders. Read SEC document |
| May 17, 2018 Filed May 21, 2018 10:50 UTC | Veritone, Inc. VERI · Entity 6925 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-18-000813 · primary_01.xml · derivative · entry 2 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of common stock. F1 · kind: Represents the automatic settlement upon vesting of restricted stock units that had been issued to reporting person on May 17, 2017. F4 · derivative.exercise_date: The restricted stock units vested on May 17, 2018. F4 · derivative.expiration_date: The restricted stock units vested on May 17, 2018. Read SEC document |
| May 17, 2018 Filed May 21, 2018 10:50 UTC | Veritone, Inc. VERI · Entity 6925 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-18-000813 · primary_01.xml · nonDerivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic settlement upon vesting of restricted stock units that had been issued to reporting person on May 17, 2017. F2 · price: The restricted stock units were converted into common stock on a one-for-one basis, and no purchase price was paid. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:53 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001252869-18-000002 · edgar.xml · derivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Acacia Research Corporation Common Stock · 100,000 shares Expires 2025-01-02 F1 · derivative.exercise_date: The option shares are execisable in six equal installments over a three-year term beginning from January 2, 2018. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:30 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,765 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001252869-17-000016 · edgar.xml · derivative · entry 2 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,295 Underlying: Acacia Research Corporation Common Stock · 11,765 shares Expires 2023-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:30 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | Exercise / conversionCommon Stock | 11,765 | $4.01 | $47,177.65 |
DisclosureSEC source: 0001252869-17-000016 · edgar.xml · nonDerivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 16:04 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | PurchaseCommon Stock | 25,000 | $3.98 | $99,382.50 |
DisclosureSEC source: 0001252869-17-000014 · edgar.xml · nonDerivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,961 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.95 to $4.00, inclusive. Mr. Walsh undertakes to provide to Acacia Research Corporation ("Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 15:45 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | PurchaseCommon Stock | 25,000 | $3.32 | $83,000.00 |
DisclosureSEC source: 0001252869-17-000012 · edgar.xml · nonDerivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,961 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.30 to $3.35, inclusive. Mr. Walsh undertakes to provide to Acacia Research Corporation ("Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 21:13 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantCommon Stock · Derivative | 50,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001252869-17-000010 · edgar.xml · derivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Acacia Research Corporation Common Stock · 50,000 shares Expires 2024-06-09 F1 · derivative.exercise_date: The option shares are exercisable in six equal installments over a three-year term with the first installment vesting on December 9, 2017. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:57 UTC | Veritone, Inc. VERI · Entity 6925 | GrantRestricted stock units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-021639 · doc1.xml · derivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Veritone common stock. F2 · derivative.exercise_date: The restricted stock units vest upon the earlier of (i) the reporting person's completion of one (1) year of Board service measured from May 17, 2017 (the "Grant Date") or (ii) the day immediately preceding the date of the regular annual stockholders meeting after the Grant Date. F2 · derivative.expiration_date: The restricted stock units vest upon the earlier of (i) the reporting person's completion of one (1) year of Board service measured from May 17, 2017 (the "Grant Date") or (ii) the day immediately preceding the date of the regular annual stockholders meeting after the Grant Date. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:56 UTC | Veritone, Inc. VERI · Entity 6925 | GrantRestricted stock units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-021638 · doc1.xml · derivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Veritone common stock. F2 · derivative.exercise_date: The restricted stock units vest upon the earlier of (i) the reporting person's completion of one (1) year of Board service measured from May 17, 2017 (the "Grant Date") or (ii) the day immediately preceding the date of the regular annual stockholders meeting after the Grant Date. F2 · derivative.expiration_date: The restricted stock units vest upon the earlier of (i) the reporting person's completion of one (1) year of Board service measured from May 17, 2017 (the "Grant Date") or (ii) the day immediately preceding the date of the regular annual stockholders meeting after the Grant Date. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 22:18 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,764 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001252869-17-000008 · edgar.xml · derivative · entry 2 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,060 Underlying: Acacia Research Corporation Common Stock · 11,764 shares Expires 2023-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 22:18 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | Exercise / conversionCommon Stock | 11,764 | $4.01 | $47,173.64 |
DisclosureSEC source: 0001252869-17-000008 · edgar.xml · nonDerivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:17 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantStock Option (Right to Buy) · Derivative | 54,299 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001252869-17-000006 · edgar.xml · derivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,299 Underlying: Acacia Research Corporation Common Stock · 54,299 shares Expires 2024-03-15 F1 · derivative.exercise_date: The option shares are exercisable in six equal installments over a three year period from March 15, 2017. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:05 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | PurchaseCommon Stock | 7,335 | $5.05 | $37,041.75 |
DisclosureSEC source: 0001252869-17-000004 · edgar.xml · nonDerivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,197 Read SEC document |
| March 13, 2017 Filed Mar 14, 2017 22:24 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | PurchaseCommon Stock | 28,703 | $5.10 | $146,385.30 |
DisclosureSEC source: 0001252869-17-000002 · edgar.xml · nonDerivative · entry 4 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,862 Read SEC document |
| March 13, 2017 Filed Mar 14, 2017 22:24 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | PurchaseCommon Stock | 10,382 | $5.08 | $52,688.65 |
DisclosureSEC source: 0001252869-17-000002 · edgar.xml · nonDerivative · entry 3 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,159 Read SEC document |
| March 13, 2017 Filed Mar 14, 2017 22:24 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | PurchaseCommon Stock | 5,680 | $5.05 | $28,684.00 |
DisclosureSEC source: 0001252869-17-000002 · edgar.xml · nonDerivative · entry 2 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,777 Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 22:24 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,333 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001252869-17-000002 · edgar.xml · derivative · entry 5 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,667 Underlying: Acacia Research Corporation Common Stock · 8,333 shares Expires 2023-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 22:24 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | Exercise / conversionCommon Stock | 8,333 | $5.75 | $47,914.75 |
DisclosureSEC source: 0001252869-17-000002 · edgar.xml · nonDerivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 16:44 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,764 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001252869-16-000018 · edgar.xml · derivative · entry 2 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,824 Underlying: Acacia Research Corporation Common Stock · 11,764 shares Expires 2023-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 16:44 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | Exercise / conversionCommon Stock | 11,764 | $4.01 | $47,173.64 |
DisclosureSEC source: 0001252869-16-000018 · edgar.xml · nonDerivative · entry 1 Walsh Frank E. III · CIK 0001252869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.